Advances in Small-Cell Lung Cancer: Recognizing the Potential of Immune Checkpoint Inhibitors and Antibody–Drug Conjugates

Review key data and expert commentary on new agents and where they fit into the optimal management of patients with SCLC with these downloadable slides and expert-authored module developed by Anna F. Farago MD PhD Matthew D. Hellmann MD and Taofeek K. Owonikoko MD PhD MSCR.

Share

Program Content

Activities

Immunotherapy and ADCs in SCLC
Immune Checkpoint Inhibitors and Antibody–Drug Conjugates in Small-Cell Lung Cancer
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: October 24, 2017

Expires: October 23, 2018

Activities

Rova-T in Advanced SCLC
The Premise and Promise of Rovalpituzumab Tesirine, a New Antibody–Drug Conjugate, in Small-Cell Lung Cancer
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: November 03, 2017

Expires: November 02, 2018

Nivolumab ± Ipilimumab in Advanced SCLC
Immunotherapy: An Intriguing Work in Progress for the Treatment of Advanced SCLC
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Faculty

cover img faculity

Daniel Morgensztern, MD

Assistant Professor
Division of Oncology
Department of Medicine
Washington University
St Louis, Missouri

Provided by

ProCE Banner

Supporters

This activity is supported by educational grants from

AbbVie

Bristol Myers Squibb